申请人:Chu Lin
公开号:US20110207750A1
公开(公告)日:2011-08-25
This invention provides compounds of Formula I which are PAFR antagonists: I and the pharmaceutically acceptable salts thereof. The compounds are useful for treating PAF-mediated disorders, and can be used in methods for treating atherosclerosis and preventing or reducing risk for atherosclerotic disease events. The compounds are also useful for treating or ameliorating pain, e.g. inflammatory pain and/or nociceptive pain, and for treating or ameliorating autoimmune and/or inflammatory diseases, among other conditions.
本发明提供了公式I的化合物,其为PAFR拮抗剂:I及其药学上可接受的盐。该化合物可用于治疗PAF介导的疾病,并可用于治疗动脉粥样硬化并预防或减少动脉粥样硬化疾病事件的风险的方法。该化合物还可用于治疗或缓解疼痛,例如炎症性疼痛和/或伤害性疼痛,并用于治疗或缓解自身免疫和/或炎症性疾病等其他病症。